Navigation Links
MedImmune's Motavizumab Reduced RSV Hospitalizations by 83 Percent Among High-Risk Native American, Full-Term Infants in Placebo-Controlled Phase 3 study
Date:8/23/2007

GAITHERSBURG, Md., Aug. 23 /PRNewswire/ -- MedImmune, Inc. today announced that in a Phase 3 study, motavizumab was shown to reduce hospitalizations due to respiratory syncytial virus (RSV) by 83 percent as compared to placebo (8.3 percent in placebo arm vs. 1.4 percent in motavizumab; p<0.001), as the trial's primary endpoint. In addition, the trial showed a 71-percent reduction in the incidence of RSV-specific lower respiratory infections (LRIs) requiring outpatient management (9.5 percent in placebo group and 2.8 percent in the motavizumab group; p<0.001), which was a secondary endpoint.

Motavizumab is an investigational monoclonal antibody (MAb) being evaluated for its potential to prevent serious disease caused by RSV in high-risk pediatric patients. This Phase 3 trial involved 1,410 full-term infants less than six months of age in two Native American populations. In previous medical studies these populations were shown to have high rates of hospitalization due to RSV.

The randomized (2:1), double-blind study was designed to compare monthly intramuscular injections of motavizumab against placebo. After an interim analysis conducted by an independent data safety monitoring committee, the study was unblinded early due to statistical evidence demonstrating that motavizumab reduced RSV hospitalizations and LRIs requiring outpatient medical management within this population. Kate O'Brien, M.D., associate professor at the Center for American Indian Health, Johns Hopkins Bloomberg School of Public Health, served as the study's principal investigator.

"We are pleased with the results of this study which support the positive results seen in our Phase 3 pivotal trial comparing motavizumab and Synagis(R) (palivizumab) that were previously reported at the Pediatric Academic Societies meeting in May 2007," said Genevieve Losonsky, M.D., vice president, clinical development, infectious disease, MedImmune.

Motavizumab was well tolerated in these
'/>"/>

SOURCE MedImmune, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. New Study Shows That Extending Prophylaxis With Clexane / Lovenox (enoxaparin Sodium Injection) to 5 Weeks is More Effective Than 10 Days for Reducing the Risk of Venous Thromboembolism (VTE) in Acutely ill Medical Patients With Reduced Mobility
2. Publication on Pixantrone Preclinical Studies Demonstrates Reduced Cardiotoxicity Compared to Equiactive Doses of Doxorubicin and Mitoxantrone
3. New Study Shows A1c Reduced Safely By Patients With Type 2 Diabetes Using Self-Adjusted Dosing Starting With Once-Daily Insulin Treatment Levemir
4. Lipitor Reduced the Risk of Coronary Events by Half and Stroke by Nearly One-Third in High-Risk Patients with Type 2 Diabetes Who Experienced a Recent Stroke
5. New Study Shows A1c Reduced Safely By Patients With Type 2 Diabetes Using Self-Adjusted Dosing Starting With Once-Daily Insulin Treatment Levemir
6. Arterial Plaque Significantly Reduced in Women Age 50-59 Taking Hormones, Says New Analysis of Womens Health Initiative Data
7. New Analysis of WHI Data Shows Reduced Levels of Coronary Artery Calcification, a Predictor of Cardiovascular Events, in Women aged 50-59 taking Estrogen Therapy
8. Pivotal Phase III Trial Showed Promacta (eltrombopag olamine) Raised Platelet Counts and Reduced Bleeding in Patients With Chronic ITP
9. Preclinical Study Finds Protease Inhibitor-Resistant HIV May Have Reduced Potential to Develop Resistance to Panacos Bevirimat
10. New Analysis of Data Shows Treatment With Abbotts Humira (Adalimumab) Significantly Reduced Disease-Related Hospitalization for Patients with Crohns Disease
11. Data Suggest Cymbalta Reduced Severity of Night Pain in Patients with Diabetic Nerve Pain
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/27/2015)... , February 27, 2015 ... sein bahnbrechendes Überwachungssystem für kongestive Herzinsuffizienz (CHF) ... -     ... die ein neuartiges Herzüberwachungssystem für Patienten mit ... bekannt, dass sie ein Finanzierungsvorhaben über 5 ...
(Date:2/26/2015)...  Finesse expands office in Leicester, United ... expansion of its operations in Leicester ... access for customers is expected shortly afterward. ... to the current office, the new premises will double ... allow Finesse to bring on more service personnel. The ...
(Date:2/26/2015)... , Feb. 26, 2015  IRIDEX Corporation (NASDAQ: ... quarter and full year 2014 financial results after the market ... with the release, the Company will host a conference call ... on Thursday, March 5, 2015 to discuss ... Interested parties may access the live conference call via ...
Breaking Medicine Technology:Vectorious Medical Technologies schließt Finanzierungsvorhaben über 5 Mio. USD ab 2New Finesse Office in United Kingdom 2IRIDEX Announces Fourth Quarter and Full Year 2014 Conference Call and Release Date 2
(Date:2/28/2015)... 2015 Memphis, TN: MedixSafe has retracted ... a new security reader named Guardian 2. The ... a new biometric scanner that significantly increases the ... the new biometric scanner provides fast and easy ... MedixSafe narcotics lockers with Vanguard technology ...
(Date:2/28/2015)... My Shiney Hiney® LLC., the renowned brand ... Las Vegas, Nevada for the annual ASD Market Week tradeshow. ... leading consumer-goods tradeshows and My Shiney Hiney will be one ... Shiney Hiney can be found at booth number C1663. , ... at-home personal hygiene brush and cleansing system exclusively created to ...
(Date:2/27/2015)... Sacramento, Calif. (PRWEB) February 27, 2015 ... of liver-disease death, between four and 12 years earlier ... study from UC Davis Health System. , While previous ... ALD than other populations, the new study -- published ... -- is believed to be the first to pinpoint ...
(Date:2/27/2015)... Santa Clara, CA (PRWEB) February 27, 2015 ... Integrated Passive Devices (IPD), has introduced miniature, wire bondable, ... Brightness and Power LED markets. The ESD88NP ... high transient currents away from sensitive LED and IC ... compared to Multilayer Varistors (MLV). All devices meet ...
(Date:2/27/2015)... Beverly Hills, CA (PRWEB) February 27, 2015 ... was in the air for those suffering from Sjögren’s ... had been discovered by researchers at the University of ... the next phase of research was to develop a ... to precisely detect the presence of new autoantibodies. Researchers ...
Breaking Medicine News(10 mins):Health News:New Name Announced For Newest MedixSafe Readers – MedixSafe Vanguard 2Health News:My Shiney Hiney® to Participate in ASD Market Week 2015 2Health News:UC Davis Study Finds Hispanics Develop Alcoholic Liver Disease at Younger Ages than Caucasians or African Americans 2Health News:OnChip Introduces New Series of Space Saving Bare-die Zener Diodes for Transient Voltage Suppression 2Health News:OnChip Introduces New Series of Space Saving Bare-die Zener Diodes for Transient Voltage Suppression 3Health News:Breakthrough Blood Test for Early Detection of Sjögren’s Syndrome Now Available 2
... , THURSDAY, May 5 (HealthDay News) -- People with allergies ... is flooded, experts advise. Failure to remove contaminated materials ... been flooded can lead to long-term health risks, according to ... example, standing water and wet materials quickly lead to the ...
... just as effective as longer ones,- and a great ... cause pneumonia in children on temporary breathing devices, according ... May 3 in Clinical Infectious Diseases . ... antibiotics for respiratory infections while on a ventilator, longer ...
... Reston, Va. (May 5, 2011) Two articles in ... Medicine make a case for maintaining current U.S. ... patients who undergo radioactive iodine treatments for thyroid cancer, ... for patients receiving radioactive iodine after total or near-total ...
... The makers of cold and fever medications that contain the ... versions of the products to avoid confusion that might lead ... production ends, later this year, the companies will sell just ... Companies such as Johnson & Johnson currently sell infant versions ...
... This release is available in German . ... severe symptoms, which include shortness of breath, exhaustion and a ... in women, often claims the patient,s life within a few ... can slow down the progression of the disease and improve ...
... Tests of a new antibody-based "biosensor" developed by researchers at ... detect marine pollutants like oil much faster and more cheaply ... to be used from a boat. Testing of the ... drain into lower Chesapeake Bay, shows that the instrument can ...
Cached Medicine News:Health News:Short antibiotic courses safer for breathing-tube infections in children 2Health News:The case for maintaining current regulations on I-131 therapy 2Health News:Drugmakers to End Infant Formulas of Products With Acetaminophen 2Health News:Drugmakers to End Infant Formulas of Products With Acetaminophen 3Health News:When the lungs come under pressure 2Health News:When the lungs come under pressure 3Health News:Tests show new biosensor can guide environmental clean-ups 2Health News:Tests show new biosensor can guide environmental clean-ups 3Health News:Tests show new biosensor can guide environmental clean-ups 4
Used in conjunction with the E5381 600 Circling Band (40 style). Indications: Narrow scleral bed. Overall length: 100 mm, 3.9 inches....
...
...
...
Medicine Products: